Erratum: A thrombopoietin receptor antagonist is capable of depleting myelofibrosis hematopoietic stem and progenitor cells (Blood (2016)127:26 (3398-3409) DOI: 10.1182/blood-2015-10-674465);A thrombopoietin receptor antagonist is capable of depleting myelofibrosis hematopoietic stem and progenitor cells

Blood

Volumn 127, Issue 26, 2016, Pages 3398-3409

  Wang, Xiaoli ^a   Haylock, David ^b   Hu, Cing Siang ^a   Kowalczyk, Wioleta ^b   Jiang, Tianbo ^a   Qiu, Jiajing ^a   Mosoyan, Goar ^a   He, Wu ^a   Marshall, Netonia ^a   Mascarenhas, John ^a   Tarasova, Anna ^b   Brody, Joshua ^a   Winkler, David ^b,c,d,e   Hoffman, Ronald ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b CSIRO   (Australia)

^c MONASH UNIVERSITY   (Australia)

^d LA TROBE UNIVERSITY   (Australia)

^e FLINDERS UNIVERSITY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

CD34 ANTIGEN; CYCLOPEPTIDE; JANUS KINASE 2; LCP 4; RECEPTOR BLOCKING AGENT; STAT PROTEIN; THROMBOPOIETIN RECEPTOR ANTAGONIST; UNCLASSIFIED DRUG; JAK2 PROTEIN, HUMAN; MPL PROTEIN, HUMAN; THROMBOPOIETIN RECEPTOR;

ADULT; AGED; ALLELE; ANIMAL CELL; ANIMAL EXPERIMENT; ANTIGEN EXPRESSION; APOPTOSIS; ARTICLE; BURST FORMING UNIT; CELL DIFFERENTIATION; CELL PROLIFERATION; CHIMERA; CLINICAL ARTICLE; COLONY FORMING UNIT; CONTROLLED STUDY; DOWN REGULATION; ERYTHROID CELL; FEMALE; GRANULOCYTE; HEMATOPOIETIC STEM CELL; HUMAN; HUMAN CELL; JAK2V617F GENE; MACROPHAGE; MALE; MEGAKARYOCYTE; MIDDLE AGED; MOUSE; MUTATIONAL ANALYSIS; MYELOFIBROSIS; NONHUMAN; PRIORITY JOURNAL; SPLEEN CELL; STEM CELL; AMINO ACID SUBSTITUTION; ANIMAL; ANTAGONISTS AND INHIBITORS; GENETICS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; METABOLISM; MISSENSE MUTATION; PATHOLOGY; PRIMARY MYELOFIBROSIS; XENOGRAFT;

AGED; AMINO ACID SUBSTITUTION; ANIMALS; ANTIGENS, CD34; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HEMATOPOIETIC STEM CELLS; HETEROGRAFTS; HUMANS; JANUS KINASE 2; MALE; MICE; MIDDLE AGED; MUTATION, MISSENSE; PRIMARY MYELOFIBROSIS; RECEPTORS, THROMBOPOIETIN;

EID: 85017106464     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2017-11-815340     Document Type: Erratum

References (45)

1. Klampfl T, Gisslinger H, Harutyunyan AS, et al. Somatic mutations of calreticulin in myeloproliferative neoplasms. N Engl J Med. 2013;369(25):2379-2390.
2. Nangalia J, Massie CE, Baxter EJ, et al. Somatic CALR mutations in myeloproliferative neoplasms with nonmutated JAK2. N Engl J Med. 2013;369(25):2391-2405.
3. Tefferi A, Lasho TL, Finke CM, et al. CALR vs JAK2 vs MPL-mutated or triple-negative myelofibrosis: clinical, cytogenetic and molecular comparisons. Leukemia. 2014;28(7):1472-1477.
4. Tefferi A. Myelofibrosis with myeloid metaplasia. N Engl J Med. 2000;342(17):1255-1265.
5. Yoshihara H, Arai F, Hosokawa K, et al. Thrombopoietin/MPL signaling regulates hematopoietic stem cell quiescence and interaction with the osteoblastic niche. Cell Stem Cell. 2007;1(6):685-697.
6. Qian H, Buza-Vidas N, Hyland CD, et al. Critical role of thrombopoietin in maintaining adult quiescent hematopoietic stem cells. Cell Stem Cell. 2007;1(6):671-684.
7. Geddis AE, Linden HM, Kaushansky K. Thrombopoietin: a pan-hematopoietic cytokine. Cytokine Growth Factor Rev. 2002;13(1):61-73.
8. Lannutti BJ, Epp A, Roy J, Chen J, Josephson NC. Incomplete restoration of Mpl expression in the mpl-/- mouse produces partial correction of the stem cell-repopulating defect and paradoxical thrombocytosis. Blood. 2009;113(8):1778-1785.
9. Fox N, Priestley G, Papayannopoulou T, Kaushansky K. Thrombopoietin expands hematopoietic stem cells after transplantation. J Clin Invest. 2002;110(3):389-394.
10. Wang JC, Chen C, Lou LH, Mora M. Blood thrombopoietin, IL-6 and IL-11 levels in patients with agnogenic myeloid metaplasia. Leukemia. 1997;11(11):1827-1832.
11. Wang JC, Chen C, Novetsky AD, Lichter SM, Ahmed F, Friedberg NM. Blood thrombopoietin levels in clonal thrombocytosis and reactive thrombocytosis. Am J Med. 1998;104(5):451-455.
12. Cerutti A, Custodi P, Duranti M, Noris P, Balduini CL. Thrombopoietin levels in patients with primary and reactive thrombocytosis. Br J Haematol. 1997;99(2):281-284.
13. Moliterno AR, Hankins WD, Spivak JL. Impaired expression of the thrombopoietin receptor by platelets from patients with polycythemia vera. N Engl J Med. 1998;338(9):572-580.
14. Ng AP, Kauppi M, Metcalf D, et al. Mpl expression on megakaryocytes and platelets is dispensable for thrombopoiesis but essential to prevent myeloproliferation. Proc Natl Acad Sci USA. 2014;111(16):5884-5889.
15. Meyer SC, Keller MD, Woods BA, et al. Genetic studies reveal an unexpected negative regulatory role for Jak2 in thrombopoiesis. Blood. 2014;124(14):2280-2284.
16. Yan XQ, Lacey D, Fletcher F, et al. Chronic exposure to retroviral vector encoded MGDF (mpl-ligand) induces lineage-specific growth and differentiation of megakaryocytes in mice. Blood. 1995;86(11):4025-4033.
17. Pikman Y, Lee BH, Mercher T, et al. MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia. PLoS Med. 2006;3(7):e270.
18. Spivak JL, Merchant A, Williams DM, et al. A functional thrombopoietin receptor is required for full expression of phenotype in a JAK2 V617F transgenic mouse model of polycythemia vera [abstract]. Blood. 2012;120(21). Abstract 427.
19. Sangkhae V, Etheridge SL, Kaushansky K, Hitchcock IS. The thrombopoietin receptor, MPL, is critical for development of a JAK2V617F-induced myeloproliferative neoplasm. Blood. 2014;124(26):3956-3963.
20. Barosi G, Rosti V, Massa M, et al. Spleen neoangiogenesis in patients with myelofibrosis with myeloid metaplasia. Br J Haematol. 2004;124(5):618-625.
21. Thiele J, Pierre R, Imbert M, et al. Chronic idiopathic myelofibrosis. In: Jaffe ES, Harris N, Stan N, Vardiman JW, eds. World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues. Lyon, France: IARC Press; 2001:35-38.
22. Wang X, Zhang W, Tripodi J, et al. Sequential treatment of CD341 cells from patients with primary myelofibrosis with chromatin-modifying agents eliminate JAK2V617F-positive NOD/SCID marrow repopulating cells. Blood. 2010;116(26):5972-5982.
23. Nussenzveig RH, Swierczek SI, Jelinek J, et al. Polycythemia vera is not initiated by JAK2V617F mutation. Exp Hematol. 2007;35(1):32-38.
24. Wu Z, Zhang Y, Zhang X, et al. A multiplex snapback primer system for the enrichment and detection of JAK2 V617F and MPL W515L/K mutations in Philadelphia-negative myeloproliferative neoplasms. Biomed Res Int. 2014;2014:458457.
25. Wang X, Ye F, Tripodi J, et al. JAK2 inhibitors do not affect stem cells present in the spleens of patients with myelofibrosis. Blood. 2014;124(19):2987-2995.
26. Li Z, Xu M, Xing S, et al. Erlotinib effectively inhibits JAK2V617F activity and polycythemia vera cell growth. J Biol Chem. 2007;282(6):3428-3432.
27. Moliterno AR, Siebel KE, Sun AY, Hankins WD, Spivak JL. A novel thrombopoietin signaling defect in polycythemia vera platelets. Stem Cells. 1998;16(suppl 2):185-192.
28. Kaushansky K. Thrombopoietin and the hematopoietic stem cell. Ann N Y Acad Sci. 2005;1044:139-141.
29. Wang X, Prakash S, Lu M, et al. Spleens of myelofibrosis patients contain malignant hematopoietic stem cells. J Clin Invest. 2012;122(11):3888-3899.
30. Lu X, Levine R, Tong W, et al. Expression of a homodimeric type I cytokine receptor is required for JAK2V617F-mediated transformation. Proc Natl Acad Sci USA. 2005;102(52):18962-18967.
31. Harrison C, Kiladjian JJ, Al-Ali HK, et al. JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis. N Engl J Med. 2012;366(9):787-798.
32. Verstovsek S, Mesa RA, Gotlib J, et al. A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis. N Engl J Med. 2012;366(9):799-807.
33. Manshouri T, Quintás-Cardama A, Nussenzveig RH, et al. The JAK kinase inhibitor CP-690,550 suppresses the growth of human polycythemia vera cells carrying the JAK2V617F mutation. Cancer Sci. 2008;99(6):1265-1273.
34. Moliterno AR, Spivak JL. Posttranslational processing of the thrombopoietin receptor is impaired in polycythemia vera. Blood. 1999;94(8):2555-2561.
35. Horikawa Y, Matsumura I, Hashimoto K, et al. Markedly reduced expression of platelet c-mpl receptor in essential thrombocythemia. Blood. 1997;90(10):4031-4038.
36. Pecquet C, Diaconu CC, Staerk J, et al. Thrombopoietin receptor down-modulation by JAK2 V617F: restoration of receptor levels by inhibitors of pathologic JAK2 signaling and of proteasomes. Blood. 2012;119(20):4625-4635.
37. Wang X, Hu CS, Li Y, Hoffman R. Thrombopoietin affects the behavior of myelofibrosis stem cells [abstract]. Blood. 2014;124(21). Abstract 2145.
38. Miyakawa Y, Oda A, Druker BJ, et al. Recombinant thrombopoietin induces rapid protein tyrosine phosphorylation of Janus kinase 2 and Shc in human blood platelets. Blood. 1995;86(1):23-27.
39. Gurney AL, Wong SC, Henzel WJ, de Sauvage FJ. Distinct regions of c-Mpl cytoplasmic domain are coupled to the JAK-STAT signal transduction pathway and Shc phosphorylation. Proc Natl Acad Sci USA. 1995;92(12):5292-5296.
40. Drachman JG, Griffin JD, Kaushansky K. The c-Mpl ligand (thrombopoietin) stimulates tyrosine phosphorylation of Jak2, Shc, and c-Mpl. J Biol Chem. 1995;270(10):4979-4982.
41. Alexander WS, Maurer AB, Novak U, Harrison-Smith M. Tyrosine-599 of the c-Mpl receptor is required for Shc phosphorylation and the induction of cellular differentiation. EMBO J. 1996;15(23):6531-6540.
42. Drachman JG, Kaushansky K. Dissecting the thrombopoietin receptor: functional elements of the Mpl cytoplasmic domain. Proc Natl Acad Sci USA. 1997;94(6):2350-2355.
43. Miyakawa Y, Rojnuckarin P, Habib T, Kaushansky K. Thrombopoietin induces phosphoinositol 3-kinase activation through SHP2, Gab, and insulin receptor substrate proteins in BAF3 cells and primary murine megakaryocytes. J Biol Chem. 2001;276(4):2494-2502.
44. Solar GP, Kerr WG, Zeigler FC, et al. Role of c-mpl in early hematopoiesis. Blood. 1998;92(1):4-10.
45. Ninos JM, Jefferies LC, Cogle CR, Kerr WG. The thrombopoietin receptor, c-Mpl, is a selective surface marker for human hematopoietic stem cells. J Transl Med. 2006;4:9.